Invivyd presented preclinical IDWeek 2026 data on VMS063, an investigational antibody that neutralized B3 and D8 measles variants in vitro.
|Articles|November 1, 1999
Supplements and Featured Publications
- The Clinical and Economic Impact of Pneumococcal Disease in the Pediatric Population
- Volume 5
- Issue 17 Suppl
Economic Impact of Pneumococcal Conjugate Vaccine in Managed Care
Author(s)Tracy Lieu, MD, MPH
Advertisement
Articles in this issue
about 27 years ago
Participating Facultyabout 27 years ago
Introductionabout 27 years ago
Epidemiology of Pneumococcal Diseaseabout 27 years ago
The Costs of Antimicrobial Treatment Failure in Acute Otitis Mediaabout 27 years ago
Prevention of Pneumococcal Disease in High-Risk Pediatric Groupsabout 27 years ago
The Clinical Impact of Pneumococcal Conjugate Vaccinesabout 27 years ago
Into the Era of the Pneumococcal Conjugate Vaccineabout 27 years ago
Selected Abstractsabout 27 years ago
CME Quizabout 27 years ago
BibliographyAdvertisement
Related to this article
In more than 250,000 adults with prediabetes and obesity, GLP-1 users had lower risks of type 2 diabetes, death, and cardiovascular events.
Sphingolipid profiles in plasma and breath condensate differed between IPF and f-HP and tracked with disease severity, CHEST 2026 data show.
The FDA granted accelerated approval to the first plasmid DNA-based immunotherapy for adults with recurrent respiratory papillomatosis (RRP).
In nearly 443,000 US adults, both low-frequency and heavy cannabis use were linked to higher odds of cardiovascular disease, led by stroke.
Clinicians separate idiopathic hypersomnia from depression-related sleepiness and interpret real-world and trial data for better outcomes.
Erythema-based criteria miss skin of color, urging ROSCO phenotyping to improve diagnostic equity in dermatology.
New abstracts show the oral PCSK9 inhibitor cut LDL-C by 57% to 63% across PREVENT risk groups, with reductions maintained in an extension study.
Advertisement
Advertisement
Trending on AJMC
1
As Employers Pull Back on GLP-1s, Andel and Novo Offer a Workaround
2
Enlicitide LDL-C Lowering Holds Across Risk Levels Up to 2 Years
3
FDA Approves First Plasmid DNA-Based Immunotherapy for Adults With RRP
4
HS Comorbidities: Navigating Metabolic, Bowel, Cardiovascular, and Mental Health Risks
5